BACKGROUND: Among the subtypes of acute myeloid leukemia, acute promyelocytic leukemia (APL) is a distinctive one. There are no published data regarding APL in Kurdistan, Iraq, so the data on this disease is limited.
Introduction
I n 1957, acute promyelocytic leukemia (APL) was recognized as a unique subtype of acute myeloid leukemia (AML), representing 5%-15% of total AML cases. [1] The reciprocal translocation between chromosome 15 and 17 in addition to the morphological features are used for the identification of this disease. [2] APL has the highest cure rate among AML subtypes. [3, 4] There are limited reports on the epidemiology of APL. [5] However, in the recent years, there was increased interest in the epidemiology of the specific types of leukemia. Since APL is a rare disease, epidemiologic data on this disease can be acquired only from large collaborative multicenter researches. [6] In the period that preceded the discovery of differentiating agents like all-trans retinoic acid (ATRA) in the mid-1980s and arsenic trioxide (ATO) in 1996, APL was associated with high rates of mortality because of bleeding complications during induction therapy. [7] With the introduction of these agents, the natural history of APL had changed, as they induce differentiation and maturation of leukemic promyelocytes to neutrophils. [8] [9] [10] Bleeding complications, infections, and differentiation syndrome (DS) are important causes of induction failure and mortality, [11, 12] on the other hand, unresponsiveness to treatment is rarely encountered during the induction phase. [8, 13] There are no published data regarding APL in Kurdistan, Iraq, so the records on this disease are limited. The aims of this study was to recognize the epidemiology, clinical presentation, and to find out the outcome among APL patients in our center in Erbil city.
Patients and Methods
This retrospective, descriptive study was carried out at Nanakali Hospital for blood diseases and cancer in Erbil. Nanakali Center is a 100-bed tertiary care hospital that receives pediatric and adult patients with benign and malignant hematological diseases and solid tumors.
Inclusion and exclusion criteria
All APL patients who were ≥18 years old from January 2007 to December 2016 were reviewed. The diagnosis of APL was based on French-American-British classification system. Cytogenetics and flow cytometry were done whenever possible. Patients with age <18 years old were excluded from the study, 6 patients left the hospital after diagnosis so they were excluded from the final analysis of overall survival.
Risk stratification was done for the patients according to Sanz risk score which classified patients into three groups depending on their initial white blood cell (WBC) and platelet counts. [14] • High risk: When the presenting WBC count >10 × 10 9 /L irrespective of platelets counts • Intermediate risk: When the presenting WBC count ≤10 × 10 9 /L and platelets ≤40 × 10 9 /L • Low risk: Those patients had WBC ≤10 × 10 9 /L, but their platelet count is >40 × 10 9 /L. Hemoglobin more than 10 g/dL without transfusion, absolute neutrophil count more than 1.5 × 10 9 /L, platelet count more than 100 × 10 9 /L, and a normocellular bone marrow with <5% blasts plus promyelocytes were required to achieve complete remission (CR) after induction therapy.
The basis of the treatment protocol was combination of ATRA and anthracycline (idarubicin, daunorubicin, or adriamycin). Cytarabine was added in the high-risk category. Dose modification was considered in old age patients with comorbidities.
Our study had been approved by the ethical committee of our institution, the Kurdistan Board for Medical Specialties, written informed consent was obtained from alive patients before registration.
Statistical analysis
Data were analyzed using the Statistical Package for the Social Sciences (SPSS, version22, IBM, NY, United States of America). Categorical variables were presented as proportions, while numerical variables were summarized by means and standard deviations (SDs). The Chi-square test of association was used to compare proportions. Kaplan-Meier survival curves had been plotted for the three risk categories and the log-rank (Mantel-Cox) test was used to compare the mean survival times and to show whether there is significant difference or not between the survival times. P ≤ 0.05 was considered statistically significant.
Results
From January 2007 to December 2016, 683 patients were diagnosed with AML in our center, ninety patients with APL (13.1%) had been involved in the study. Their mean age (±SD) was 37.5 ± 15.5 years, ranging from 18 to 85 years, the median was 35.5 years. More than one third (34.4%) aged <30 years. More than half (56.7%) were male, and the male: female ratio was 1.3:1 as presented death rate with age (P = 0.690), gender (P = 0.899), hemoglobin (P = 0.115), and platelets (P = 0.128).
in Table 1 , which shows that 57.8% of the patients were living outside Erbil and 68.9% were living in urban areas [ Table 1 ].
Most of our patients (91%) represented the classical (hypergranular) APL subtype versus 9% for the hypogranular variant. The majority of the patients presented with more than one sign and symptom where 71.4% of the patients presented with generalized weakness, 64.44% presented with bleeding, 48.9% presented with fever, and only 2.2% presented with thrombosis. Regarding the method of diagnosis, morphological examination of peripheral blood and bone marrow with immunochemical stains was done for all the patients, cytogenetics was done for 14 (15.6%) patients, and flow cytometry was done for those 14 patients in addition to another 25 patients, so the total was 39 patients (43.3%) as presented in Table 2 . The means, minimum, and maximum values of the patients' blood indices are presented in Table 3 .
As mentioned, 90 patients with APL presented to the hospital, six of them left the hospital before starting the management plan, and 18 patients died in the hospital before starting the chemotherapy, so what is left is 66 patients (received chemotherapy). More than two thirds (68.2%) of those 66 patients achieved CR, but 14 patients of them (31.1%) relapsed later on as presented in Table 4 which shows that 50 patients out of the 84 patients (59.5%) died at the end of the study.
The mean time of achieving CR in those patients who did not relapse was 32.9 days in comparison to 39.5 days in the relapsed category (P = 0.172).
The main reasons of mortality were infection (36%), bleeding (28%), DS (14%), and respiratory failure (10%), in addition to the other causes mentioned in Table 5 . Regarding time of death, 18 patients (36% of the dead patients) died before starting chemotherapy, 21 (42%) died during induction chemotherapy, 2 (4%) died during consolidation therapy, and the remaining 9 patients (18%) died during relapse. Hence, 11 patients achieved CR and died later on (8 due to infections and 3 due to bleeding complications), the mean time between CR and death was 467 days. Table 6 shows that 39 patients (out of 84 patients) died early (prior or during induction chemotherapy). The factors found to be significantly associated with early death were risk score and WBC count. The more the risk score, the higher the rate of early death where it is evident that the rate was 58.1% among those with high risk (P = 0.006). The early death rate was high (58.1%) among those with WBC count of more than 10 × 10 9 /L, compared with 34.4% among those with WBC count of ≤10 × 10 9 /L (P = 0.028). No significant association was detected between early Figure 1 and Table 7 show significant differences in the mean survival times of patients classified according to the risk scores into low, intermediate, and high risk. Table 6 shows that the higher the risk, the less the mean survival time which was 1977.31 days among those with low risk and 822.41 days among those with high risk (P = 0.001). The 5-year survival rate was 37.8% as shown in Figure 2 .
Discussion
Based on our information, this maybe the first record from Iraq outlining a 10-year practice concerning APL. No considerable difference from preceding data was noticed in regard to demographics. Young age at presentation is a frequent finding, the median age is around 30s. Our study revealed similar results to those done by Sanz et al. [14] and Mandelli et al. [15] regarding median age. Until now, no sex prediction was expressed in the former epidemiological reviews, also our study showed the same. [6, [16] [17] [18] Most of our patients were from the urban area, a finding that is supported by large multicenter study of 1400 APL patients. [19] Typically, patients were symptomatic at time of presentation to the hospital, usually bleeding, fever, fatigue, or those with thrombosis. In our study, the main presenting symptom was generalized weakness (71%) and bleeding was reported in 64.4% of the patients, a finding that is slightly lower in those researches described from New Delhi (69.7%), Cairo (79%), and Abu Dhabi (81%). [17, [20] [21] [22] In agreement with previous reports, [17, 23] half of our patients presented with fever. The incidence of thrombotic events ranged from 2% to 10% in previous reviews, [24, 25] in our group, it was 2.2%. Hence, the clinical presentations of our patients are comparable to the published articles.
Referral delay of the majority of our patients may explain the finding of having more than half of them to the high-risk group in comparison to 20%-40% in many previous reports, as most of our patients were living outside Erbil city. [16, 22, 23, [26] [27] [28] [29] Deficient understanding for the disease seriousness by the patients, financial issues, and the general practitioners may not assume the diagnosis early, all justify presenting late.
Regardless of the progress in outcome of APL, early death presents the main causative factor for treatment failure. Early death rates between patients with APL testified in the literature vary widely, a Turkish study reported a high incidence of early death at 40%, [30] 32% was reported in a Brazilian study, [31] and a Greek study found the rate to be 14.9% [28] and 61% in Pakistan, [8] and 14.6% in a Tunisian study. [32] Here, we report early death of 46% among our patients which is on the high side in comparison with the mentioned studies. The probable explanation for the high early mortality is possibly attributable to the high percentage of high-risk category in our study; another explanation could be the delay in referral of the patients which consequently delayed the administration of ATRA and supportive treatment. In agreement with previous reports, elevated WBC count and high-risk score associated with high rates of early mortality. [26, [33] [34] [35] [36] [37] [38] [39] This study showed the lower CR rates and overall survival and higher rate of relapse in comparison with other reports. [16, 20, 23, 32, 40, 41] Many factors contributed to these findings; the high number of high-risk patients, the high early mortality rate, the high incidence of infections along with inaccessibility to highly specialized microbiological laboratories, in addition to the unavailability of ATO in our area in most of the study period. Molecular evaluation (detection of minimal residual disease and molecular relapse) have been shown an important tool in guiding further therapy and early treatment of molecular proven relapse showed better results than waiting until morphological relapse, [42] those techniques were not available in our center and blamed to be one of the causes of late intervention and higher mortality.
A significant association between the overall survival and risk score had been shown in our study, prognosis among patients who are in the high-risk group is typically expected to be bad. Similar results were reported by other international studies. [8, 23, 36, 43, 44] Regarding the causes of death in our study, infections were the main cause of death followed by bleeding, in contrast with other studies which showed hemorrhage as the main cause of death. [8, 11, 23, 30, 45, 46] Late presentation to the hospital and delayed receiving treatment, absence of isolation rooms in our center, lack of accurate microbial cultures, and inability of most of our patients to afford expensive drugs like antifungals are likely explanations for the high percentage of infections. Hence, early diagnosis, prompt treatment with standard chemotherapy protocols, more intensive support treatment including early access to facilities for treatment and prevention of coagulopathy, and early recognition and treatment of DS is therefore essential in improving survival of APL patients. The most common hemorrhagic sites in our patients are the brain and lung, which is similar to other studies. [39, 45, 47] 
Conclusion
The conclusions were drawn from our retrospective study; the clinical and epidemiological features were comparable with previously published studies. High-risk patients predominate in our study population. Early mortality rate was very high, high WBC count on presentation, and high-risk score were significant predictors. Mortalities were mostly due to infections, hemorrhagic events, and DS. Despite the remarkable improvement in the therapeutics of APL, the overall survival in our center is still low as high-risk patients have significant higher risk of mortality.
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